Adding
UPTRAVI® (selexipag)
 
Delaying PAH progression starts with you
Are you armed with information you need to ask your doctor about delaying PAH progression?
Sign up for more information
What is UPTRAVI?
UPTRAVI is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.1
UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.1
It is not known if UPTRAVI is safe and effective in children.1
Watch this video
to learn more
There are steps you can take that may delay PAH progression and it starts with talking to your doctor.
IN A CLINICAL TRIAL
UPTRAVI reduced the risk of PAH disease progression* by 40%.1
27% of patients treated with UPTRAVI experienced a PAH disease progression event vs 41.6% of patients not taking UPTRAVI.1
UPTRAVI reduced the risk of PAH-related hospitalizations. This benefit was demonstrated in a clinical trial comparing patients taking UPTRAVI to those not taking UPTRAVI. Patients took UPTRAVI for an average of 1.4 years.1
In this same clinical trial, patients taking UPTRAVI walked an average of 12 meters (about 39 feet) farther than patients not taking UPTRAVI, as measured by the 6-minute walk distance (6MWD).1
*In a clinical trial of UPTRAVI, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.
How the study was conducted:
UPTRAVI was studied in the largest trial of any FDA-approved PAH treatment1
  • The trial included 1156 total PAH patients.
    • Compared 574 patients taking UPTRAVI with 582 patients taking placebo (a sugar pill)
  • 80% of enrolled patients were treated with an endothelin receptor antagonist (ERA), phosphodiesterase type-5 inhibitor (PDE-5 inhibitor), or both for PAH
  • 20% of enrolled patients were not on any PAH treatment
  • Nearly all patients were FC II or FC III (PAH patients range from FC I to FC IV)
  • Patients taking UPTRAVI were treated for an average of 1.4 years during this study
  • The trial included the most scleroderma-related PAH patients of any PAH trial (170 out of 1156)3,4
Play a role in the conversation. Ask your doctor ABOUT UPTRAVI.
Even on a good day, your PAH could be progressing.5
UPTRAVI can help delay disease progression when used alone or in combination with other PAH medications (an ERA, a PDE-5i or both).1
Learn how to discuss UPTRAVI with your doctor and start exploring an additional angle to help delay disease progression by downloading this doctor discussion guide.
DOWNLOAD DOCTOR DISCUSSION GUIDE
IMPORTANT SAFETY INFORMATION
EXPAND +
What is the most important information about UPTRAVI?
Who should not take UPTRAVI?
  • Do not take UPTRAVI if you take gemfibrozil because this medicine may affect how UPTRAVI works and cause side effects
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

What should I tell my doctor before taking UPTRAVI?

Tell your doctor if you:

  • Have liver problems
  • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
  • Are pregnant or plan to become pregnant. It is not known if UPTRAVI will harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI passes into your breast milk. You and your doctor should decide if you will take UPTRAVI or breastfeed. You should not do both
  • Have any other medical conditions
  • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What are the possible side effects of UPTRAVI?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI and all other medicines away from children.

What other medicines might interact with UPTRAVI?
  • UPTRAVI and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor
How should I take UPTRAVI?
  • Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
  • Swallow UPTRAVI tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI
  • UPTRAVI is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

+
IMPORTANT SAFETY INFORMATION
What is the most important information about UPTRAVI?
+
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension

IMPORTANT SAFETY INFORMATION
What is the most important information about UPTRAVI?
Who should not take UPTRAVI?
  • Do not take UPTRAVI if you take gemfibrozil because this medicine may affect how UPTRAVI works and cause side effects
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

What should I tell my doctor before taking UPTRAVI?

Tell your doctor if you:

  • Have liver problems
  • Have narrowing of the pulmonary veins (veins in your lungs). This is called pulmonary veno-occlusive disease (PVOD)
  • Are pregnant or plan to become pregnant. It is not known if UPTRAVI will harm your unborn baby
  • Are breastfeeding or plan to breastfeed. It is not known if UPTRAVI passes into your breast milk. You and your doctor should decide if you will take UPTRAVI or breastfeed. You should not do both
  • Have any other medical conditions
  • Are taking any other prescription or over-the-counter medicines, vitamins, or herbal supplements
What are the possible side effects of UPTRAVI?

The most common side effects are:

  • Headache
  • Diarrhea
  • Jaw pain
  • Nausea
  • Muscle pain
  • Vomiting
  • Pain in arms or legs
  • Temporary reddening of the skin (flushing)
  • Joint pain
  • Low red blood cell count
  • Less appetite than usual
  • Rash

Talk to your doctor if you have a side effect that bothers you or does not go away. These are not all the possible side effects of UPTRAVI. For more information, ask your doctor or pharmacist.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Keep UPTRAVI and all other medicines away from children.

What other medicines might interact with UPTRAVI?
  • UPTRAVI and other medicines may affect each other, causing side effects. Tell your doctor about all the medicines you are taking. Do not start any new medicine until you check with your doctor
How should I take UPTRAVI?
  • Take UPTRAVI exactly as your doctor tells you to take it. Usually, your doctor will have you take UPTRAVI twice a day. Taking UPTRAVI with food may help you tolerate UPTRAVI better
  • Swallow UPTRAVI tablets whole. Do not split, crush, or chew tablets
  • Tell your doctor if you have any form of liver disease. Your doctor may need to change your dose of UPTRAVI
  • UPTRAVI is measured in micrograms (mcg). Tablets come in the following strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg
What is UPTRAVI?

UPTRAVI® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.

UPTRAVI can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.

It is not known if UPTRAVI is safe and effective in children.

References: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294. 3. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50(2). 4. Aithala R, Alex A, Debashish D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis. 2017;20:5-24. 5. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143-155.